These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7607586)

  • 1. [Repeated passive immunotherapy delays AIDS progression].
    Paris KA
    Fortschr Med; 1995 May; 113(14):13. PubMed ID: 7607586
    [No Abstract]   [Full Text] [Related]  

  • 2. [One antibody preparation is not another: the role of passive immunotherapy in the treatment of HIV infection].
    Leverstein-van Hall MA; Goudsmit J
    Ned Tijdschr Geneeskd; 1995 Feb; 139(7):316-20. PubMed ID: 7877699
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunopathogenesis and immunotherapy in AIDS virus infections.
    Letvin NL; Walker BD
    Nat Med; 2003 Jul; 9(7):861-6. PubMed ID: 12835706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotherapy of AIDS.
    Biotherapy; 1990; 2(2):103-81. PubMed ID: 2400631
    [No Abstract]   [Full Text] [Related]  

  • 5. [The relevance of phenotypic markers for progression in AIDS in HIV-1+ children].
    Zugun F; Sfartz S; Carasevici E
    Bacteriol Virusol Parazitol Epidemiol; 1995; 40(3-4):253-6. PubMed ID: 8640013
    [No Abstract]   [Full Text] [Related]  

  • 6. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man.
    Martin-Rico P; Pedersen C; Skinhøj P; Nielsen C; Lindhardt BO
    AIDS; 1995 Jan; 9(1):95-6. PubMed ID: 7893450
    [No Abstract]   [Full Text] [Related]  

  • 7. Battling AIDS.
    Nat Struct Biol; 1999 Oct; 6(10):895-6. PubMed ID: 10504715
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-scale ex vivo expansion of primary T lymphocytes in late-stage AIDS patients.
    Shimizu N; Sekine T; Itoh K; Nakamura T; Iwamoto A; Satoh Y; Yamamoto K
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):611-2. PubMed ID: 10777152
    [No Abstract]   [Full Text] [Related]  

  • 10. Quantitation of passively acquired human immunodeficiency virus (HIV) antibodies in AIDS patients transfused with a plasma that is rich in HIV antibodies.
    Lefrère JJ; Roudot-Thoraval F; Vittecoq D; Heshmati F; Audat F; Lerable J; Reed D; Petit JC; Burghoffer B; Morand-Joubert L
    Transfusion; 1996 Aug; 36(8):734-8. PubMed ID: 8780670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma.
    Vittecoq D; Chevret S; Morand-Joubert L; Heshmati F; Audat F; Bary M; Dusautoir T; Bismuth A; Viard JP; Barré-Sinoussi F
    Proc Natl Acad Sci U S A; 1995 Feb; 92(4):1195-9. PubMed ID: 7862660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aids: results with antibodies questionable].
    Paris KA
    Fortschr Med; 1992 Jun; 110(18):16. PubMed ID: 1644392
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
    Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
    J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive hyperimmune therapy: a viable treatment option for the patient with acquired immune deficiency syndrome.
    Raven NC
    J Intraven Nurs; 1994; 17(4):214-6. PubMed ID: 7965365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human trials of AIDS vaccines: novel means of passive and active immunotherapy.
    Dalgleish AG
    AIDS; 1988; 2 Suppl 1():S129-31. PubMed ID: 3147663
    [No Abstract]   [Full Text] [Related]  

  • 16. Status of HIV vaccine development.
    Minor JR
    Am J Hosp Pharm; 1994 Jul; 51(14):1816-8. PubMed ID: 7942913
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary investigation on the relation between clinical progress and anti-small monomolecular peptides antibody in individual infected with HIV].
    Xu X; Xing H; Gong W; Chen H; Si C; Wang Y; Chermann JC
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):286-7. PubMed ID: 12665943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative results of a rapid antibody test for HIV in a 16-month-old infant with AIDS.
    Zhang Y; Wang J; Wilson GJ; Tang YW; Lu HZ
    Ann Clin Lab Sci; 2008; 38(3):293-5. PubMed ID: 18715861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulation in HIV-1 infection in the HAART era.
    Imami N; Sullivan AK; Gotch FM
    J HIV Ther; 2001 Nov; 6(4):77-84. PubMed ID: 11740408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.